Drug Profile
Research programme: phosphodiesterase 4 inhibitors - Orexo
Latest Information Update: 07 Feb 2011
Price :
$50
*
At a glance
- Originator Biolipox
- Developer Orexo
- Class
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Asthma; Chronic obstructive pulmonary disease; Inflammation